Takanobu Kuroita

This inventor holds 16 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Takeda Pharmaceutical Company Limited, Mitsubishi Pharma Corporation. Active years: 2002-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takanobu Kuroita. Retrieved from https://idiyas.com/inventor/takanobu-kuroita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 6)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 46(Granted Patents)

Location History:

Hirakata, JP (2002)
Tokyo, JP (2004 - 2007)
Katano, JP (2006 - 2011)
Kanagawa, JP (2014)
Osaka, JP (2009 - 2015)

Company Filing History:

12 out of 1,232

Takeda Pharmaceutical Company Limited

patents

4 out of 73

Mitsubishi Pharma Corporation

patents

Years Active: 2002-2015

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Amide Compounds

Benzimidazole Derivatives

Pyrimidines

Triazoles

Thiazoline Derivatives

Antihypertensive Action

Insulin Sensitizing Activity

Cardiovascular Diseases

Metabolic Diseases

Central Nervous System Diseases

Phenoxypropylamine Compounds

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9221836 - Heterocyclic compound and use thereof (2015-12-29),

2. 9045436 - Heterocyclic compound and use thereof (2015-06-02),

3. 8664380 - Heterocyclic compound and use thereof (2014-03-04),

4. 8501750 - Heterocyclic compound and use thereof (2013-08-06),

5. 8466282 - Heterocyclic compound and use thereof (2013-06-18),

6. 8329691 - Amide compounds and use of the same (2012-12-11),

7. 7998968 - Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases (2011-08-16),

8. 7875637 - Benzimidazole derivative and use as a II receptor antagonist (2011-01-25),

9. 7803940 - Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases (2010-09-28),

10. 7572920 - Benzimidazole derivative and use as a II receptor antagonist (2009-08-11),

11. 7534887 - Thiazoline derivative and use of the same (2009-05-19),

12. 7196199 - Phenoxypropylamine compounds (2007-03-27),

13. 7157584 - Benzimidazole derivative and use thereof (2007-01-02),

14. 7115635 - Benzylpiperidine compound (2006-10-03),

15. 6720320 - Phenoxypropylamine compounds (2004-04-13),

Title: Takanobu Kuroita: Innovator in Heterocyclic Compounds

Introduction

Takanobu Kuroita is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of heterocyclic compounds. With a total of 16 patents to his name, Kuroita's work has had a substantial impact on the treatment of hypertension and related organ damages.

Latest Patents

Kuroita's latest patents focus on heterocyclic compounds that exhibit superior renin inhibitory activity. These compounds are useful as agents for the prophylaxis or treatment of hypertension and various organ damages attributable to hypertension. The innovative nature of his work lies in the specific formulas defined in the specifications of his patents, which include prodrugs that enhance the efficacy of these compounds.

Career Highlights

Throughout his career, Takanobu Kuroita has worked with notable companies in the pharmaceutical industry, including Takeda Pharmaceutical Company Limited and Mitsubishi Pharma Corporation. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Kuroita has collaborated with several talented individuals in his field, including Hiroki Sakamoto and Yasuhiro Imaeda. These collaborations have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Takanobu Kuroita is a distinguished inventor whose work in heterocyclic compounds has the potential to improve the treatment of hypertension and related health issues. His contributions to the pharmaceutical industry are noteworthy and continue to influence future innovations.

Profile summary based on public USPTO records.